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a significant increase in the age at the time of 
diagnosis (45 years vs 52 years) accompanied 
by an increased prevalence of obesity (31% vs 
43%), ischemic heart disease (5.8% vs 16.3%), 
and diabetes (5.7% vs 18.3%), which are impor‑
tant risk factors for left ventricular diastolic dys‑
function and, consequently, postcapillary PH.8,9 
Therefore, it has been postulated that some old‑
er patients diagnosed with PAH who still meet 
the hemodynamic criteria of precapillary PH may 
still have some degree of left ventricular diastolic 
dysfunction and constitute a unique phenotype 
of “mixed” PH.
Currently, it remains unclear whether the 
changing demographics of the PAH population 
influences the course and outcome of this severe 
disease. The recent analysis of the AMBITION 
(Ambrisentan and Tadalafil in Patients with Pul‑
monary Arterial Hypertension) trial, which was 
one of the landmark studies in PAH, is of inter‑
est in this context. This trial showed that the up‑
front combination of tadalafil and ambrisentan 
in the group of treatment ‑naive patients with 
PAH resulted in a significantly lower risk of clin‑
ical failure than observed in monotherapy with 
either ambrisentan or tadalafil. McLaughlin10 
made use of the fact that the inclusion criteria 
were revised in the course of the trial to min‑
imize the risk of enrolling patients in whom 
left ventricular diastolic dysfunction may have 
been a factor contributing to PH. Accordingly, 
the cutoff for PVR was increased from 3 WU to 
3.75 WU, and the cutoff for pulmonary artery 
wedge pressure was reduced from ≤15 mm Hg 
to ≤12 mm Hg if PVR was less than 6.25 WU. Ad‑
ditionally, patients with 3 or more risk factors 
for heart failure with reduced diastolic function 
were excluded from the study. These risk factors 
included: body mass index ≥30 kg/m2, history 
of essential hypertension, diabetes mellitus, 
and history of severe coronary artery disease. 
Patients who met the amended eligibility cri‑
teria (the primary analysis group) as compared 
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(PAH) is a rare disease in which the progressive 
narrowing of the lumen of pulmonary arteries 
leads to a rise in pulmonary arterial pressure and 
pulmonary vascular resistance (PVR). It results 
in progressive right heart failure, functional de‑
cline, and, ultimately, death. The hemodynamic 
classification of pulmonary hypertension (PH) 
places PAH within a group of precapillary PH, as‑
suming that it results entirely from the arterio‑
lar narrowing and excluding the role of a passive 
backward transmission of left ventricular filling 
pressure in its pathogenesis.1-3 Recently, the ex‑
perts of the 6th World Symposium on Pulmonary 
Hypertension proposed to define PAH as a mean 
pulmonary artery pressure (mPAP) higher than 
20 mm Hg, accompanied by elevated PVR high‑
er than 3 Wood units, and a pulmonary artery 
wedge pressure lower than or equal to 15 mm Hg.4
In the first PAH registry initiated in the 1980s 
by the US National Institutes of Health (NIH), 
the mean (SD) age of enrolled patients with pri‑
mary PH (currently referred to as idiopathic 
PAH [IPAH]) was 36 (15) years. Consequently, 
for many years, PAH was considered a disease 
that affects mainly young people. However, more 
recent epidemiological studies from the Unit‑
ed States and Western European countries in‑
dicate that the mean age of patients diagnosed 
with PAH has increased.5 For example, in the RE‑
VEAL study (Registry to Evaluate Early and Long‑
‑term PAH Disease Management) that recruited 
patients 30 years after the NIH registry had been 
compiled, the mean age in the IPAH group was 
53 years, while in the European COMPERA regis‑
try (Comparative, Prospective Registry of Newly 
Initiated Therapies for Pulmonary Hypertension), 
patients with incident IPAH were in their 70s 
at the time of diagnosis.6,7 Furthermore, the ag‑
ing of the PAH population influences its pheno‑
type. The comparison of patients with IPAH di‑
agnosed in the United Kingdom and Ireland in 
the years 2001–2003 and 2007 –2009 showed 
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with those who did not (the ex ‑primary analy‑
sis group) were younger, had greater 6 ‑minute 
walk distance, and fewer comorbidities. What 
is more, the primary analysis group had fewer 
events of clinical failure, higher rates of satis‑
factory clinical response, and lower rates of per‑
manent study drug withdrawal due to adverse 
effects than the ex ‑primary analysis group. Al‑
though the beneficial effects of the initial combi‑
nation therapy versus pooled monotherapy were 
found in both populations, they were of a low‑
er magnitude in the ex ‑primary analysis group.
Although left ventricular dysfunction and 
the so called “mixed” phenotype of PAH could 
have contributed to the worse response to treat‑
ment in the group with multiple risk factors, 
it should be acknowledged that some of them may 
directly affect pulmonary vasculature. Recently, 
several reports11-15 have documented the clinical 
impact of diabetes, insulin resistance, and im‑
paired lipid metabolism, including a low level of 
high ‑density lipoprotein cholesterol, on disease 
severity and outcome of patients with PAH. These 
risk factors have also been shown to be more prev‑
alent in patients with PAH than in age ‑matched 
controls. As the exact mechanism of these associ‑
ations is still poorly understood, further research 
is needed to elucidate this challenging new phe‑
notype of PAH.
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